Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for the combination arm vs 28% for the control arm at week 24. Post-hoc analysis from the phase 3 SENTRY trial suggests SVR35 may predict overall survival...
Ddrops® Championed Active Childhoods and Healthy Growth at Aqua Champs League Fest 2026 Malaysia
KUALA LUMPUR, Malaysia, June 14, 2026 /PRNewswire/ -- Ddrops®, a Canadian family health and nutritional supplement brand, participated as a supporting sponsor of Aqua Champs League Fest 2026 (ACLF 2026) in Malaysia, reinforcing its commitment to children's healthy growth through active lifestyles, positive family routines and simple daily nutrition. Ddrops® x Aqua Champs League Fest 2026...
Angel Yeast Releases 2025 Sustainability Report as Company Marks 40th Anniversary
SHANGHAI, June 13, 2026 /PRNewswire/ -- Angel Yeast (SSE: 600298), one of the world's leading yeast manufacturers, recently marked its 40th anniversary with the release of the 2025 Sustainability Report. Angel Yeast Releases 2025 Sustainability Report as Company Marks 40th Anniversary Structured around four key themes—Stable Development, Strong Momentum,...
Luxel Corporation Appoints KOS, Inc. as Exclusive Distributor in South Korea
FRIDAY HARBOR, Wash., June 13, 2026 /PRNewswire/ -- Luxel Corporation, a global leader in the design and manufacture of ultrathin freestanding polymer and metallized optical bandpass filters, today announced the appointment of KOS, Inc. as its exclusive distribution partner for South Korea, effective immediately. This partnership marks a significant milestone...
Global Heart Hub finds women delay seeking heart care by continuing to put others first
Heart symptoms continue to be dismissed or mistaken for other conditions, such as anxiety, new global patient-led research reveals. Findings were presented at the European Society of Cardiology's ACNAP Congress 2026, organised by the Association of Cardiovascular Nursing & Allied Professions, the leading congress for nurses and allied professionals committed to...
Gan & Lee Pharmaceuticals Achieves Significant Progress in Its Dual Pipeline for Metabolic Diseases — Weekly Insulin Ludefen (GZR4) Meets Primary Endpoint in Phase III Clinical Trial in China;...
BEIJING and BRIDGEWATER, N.J., June 12, 2026 /PRNewswire/ -- Gan & Lee Pharmaceuticals (hereinafter "Gan & Lee", stockcode: 603087.SH) announced that two of its core pipeline products in the fields of diabetes and obesity treatment have recently achieved positive clinical results. SUPER-3: Insulin Ludefen (GZR4)combined with insulin aspart demonstrated superior HbA1c...
UCB Transforms Safety Operations with Veeva Safety Suite in Collaboration with ELIQUENT Life Sciences, Pinnaxis, and Daelight Solutions
WASHINGTON, June 12, 2026 /PRNewswire/ -- ELIQUENT Life Sciences ("ELIQUENT") today announced the June 1 go-live of Veeva Safety Suite at UCB. As one of the first organizations to adopt the complete suite, UCB is unifying its global safety operations in a transformation delivered through a strategic collaboration between Veeva, ELIQUENT,...
Church Leaders Join Mayor Linda Aitken in Prayer for WA’s Fastest Growing City
PERTH, Australia, June 12, 2026 /PRNewswire/ -- Church leaders from across the City of Wanneroo gathered with Mayor Linda Aitken on Friday 12 June for the Wanneroo Prayer Breakfast, held at the Wanneroo Civic Centre, coming together to pray for the city and hear first-hand about the challenges facing Western Australia's fastest growing community. The...
Simcere Pharmaceutical Enters into a Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients with Idiopathic Pulmonary Fibrosis
SHANGHAI, June 12, 2026 /PRNewswire/ -- On May 29, 2026, Pacific Time, Simcere Pharmaceutical Group Limited (2096.HK) entered into a research collaboration agreement with Stanford Medicine to jointly advance an exploratory study in the respiratory field, with the aim of developing innovative therapies for patients with idiopathic pulmonary fibrosis (IPF). According to the agreement, Simcere Pharmaceutical will fund the...
Akeso’s Gumokimab (AK111, Anti-IL-17) Approved by NMPA for Moderate-to-Severe Plaque Psoriasis, Bolstering Its Autoimmune Disease Portfolio
HONG KONG, June 12, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced that the National Medical Products Administration (NMPA) of China has approved gumokimab (AK111), the company's internally-developed anti-IL-17 monoclonal antibody, for the treatment of adult patients with moderate-to-severe plaque psoriasis. The approval was supported by one pivotal Phase III clinical study (AK111-301) and three supportive studies. Study...
